A Mouse Model for PACS1 Syndrome
The technology features a mouse model designed with a megamer-based CRISPR/Cas9 genome editing strategy that replicates a human de novo missense mutation associated with a neurodevelopmental disorder. This model precisely introduces the analogous R201W mutation in mice, allowing direct in vivo analysis of neurodevelopmental deficits. It provides researchers with a critical tool to dissect underlying biological mechanisms and evaluate potential therapeutic interventions in a controlled, whole-organism setting. Unlike cell-based systems, this model supports comprehensive studies of the disorder’s effects on brain development and function.
Description
This approach is differentiated by its unique ability to reproduce the human mutation in a murine system, making it the first of its kind for this rare condition. Its innovative design bypasses limitations of existing iPSC and fibroblast models by offering a more physiologically relevant platform. Researchers can observe real-time neurological and behavioral outcomes, which enhances understanding of the disorder’s pathophysiology and accelerates the development of effective treatments.Applications
- Preclinical drug evaluation model- Therapeutic compound screening
Advantages
- Enables direct in vivo investigation of neurodevelopmental deficits associated with PACS1 Syndrome.- Serves as a unique alternative to cell-based models, enhancing drug discovery and therapeutic evaluation.
- Facilitates mechanistic studies to understand the underlying biological causes of the disorder.
- Utilizes a novel megamer-based CRISPR/Cas9 strategy, improving precision in genetic modeling.